Format

Send to

Choose Destination
See comment in PubMed Commons below
Biomarkers. 2012 Dec;17(8):706-13. doi: 10.3109/1354750X.2012.719037. Epub 2012 Sep 24.

Galectin 3 complements BNP in risk stratification in acute heart failure.

Author information

1
Department of Emergency Medicine, University of Cincinnati, Cincinnati, OH 34267-0769, USA. gregory.fermann@uc.edu

Abstract

BACKGROUND:

Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure.

METHODS:

Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial.

RESULTS:

Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide.

CONCLUSION:

In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

PMID:
22998064
PMCID:
PMC3678263
DOI:
10.3109/1354750X.2012.719037
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center